SCHEMBL8653315

SCHEMBL8653315

CC1(C(=O)O)CCc2cc(O)ccc2O1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.50
PPARA Q07869 11/20 0.44
PPARG P37231 7/20 0.44
HIF1A Q16665 1/20 0.44
EPAS1 Q99814 1/20 0.44
PTPN1 P18031 1/20 0.44
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
RXRA P19793 1/20 0.43
PPARD Q03181 1/20 0.43
CYSLTR2 Q9NS75 1/20 0.42
CYSLTR1 Q9Y271 1/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797538 0.88 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL19469595 0.87 PPARA (0.46) PPARAPPARGRXRAPPARD
SCHEMBL19469460 0.87 PPARA (0.46) PPARAPPARGRXRAPPARD
SCHEMBL19469681 0.87 PPARA (0.46) PPARAPPARGRXRAPPARD
SCHEMBL23618118 0.84 PPARA (0.47) AKT1PPARAHIF1AEPAS1PTPN1
SCHEMBL22798929 0.84 PPARA (0.44) PPARAPPARGRXRAPPARDCYSLTR2
SCHEMBL22129840 0.84 EPHX2 (0.47) PPARAPPARGRXRAPPARDCYSLTR2
SCHEMBL10636265 0.81 AKT1 (0.47) AKT1PPARAPPARGMGAMGAA
SCHEMBL3519974 0.80 TRPM8 (0.47) PPARAPPARGPPARDPTGS1PTGS2
SCHEMBL29455981 0.80 TRPM8 (0.47) PPARAPPARGPPARDPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584728-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2023-02-21 US disclosed
US-20210206736-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. 2021-07-08 US disclosed
EP-0604995-B1 Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena LIFEGROUP SPA (IT) 1998-09-30 EP disclosed
US-5480645-A Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena LIFEGROUP S.P.A. (IT) 1996-01-02 US disclosed
EP-0604995-A1 Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomena LIFEGROUP S.p.A. (IT) 1994-07-06 EP disclosed
US-4788214-A ANTIALLERGENS HOFFMAN-LA ROCHE INC. (US) 1988-11-29 US disclosed
US-4785017-A ANTIALLERGENS HOFFMANN-LA ROCHE INC. (US) 1988-11-15 US disclosed
EP-0129906-B1 PHENOXYALKOXY-3,4-DIHYDRO-2H-1-BENZOPYRAN DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1988-06-08 EP disclosed
US-4026907-A INTERMEDIATES FOR ALPHA-TOCOPHEROL HOFFMANN-LA ROCHE INC. (US) 1977-05-31 US disclosed
US-4018799-A INTERMEDIATES FOR TOCOPHEROL HOFFMANN-LA ROCHE INC. (US) 1977-04-19 US disclosed
US-4003919-A INTERMEDIATES FOR ALPHA-TOCOPHEROL HOFFMANN-LA ROCHE INC. (US) 1977-01-18 US disclosed
US-3947473-A (6-HYDROXY-CHROMAN-2-YL) CARBOXYLIC ACID DERIVATIVES HOFFMAN-LA ROCHE INC. (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584728-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia FH, COQ8A, TFAM AKT1 3015/4885PPARA 967/4885PPARG 454/4885
US-20210206736-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM AKT1 3015/4885PPARA 967/4885PPARG 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.